JP2024505250A5 - - Google Patents
Info
- Publication number
- JP2024505250A5 JP2024505250A5 JP2023546234A JP2023546234A JP2024505250A5 JP 2024505250 A5 JP2024505250 A5 JP 2024505250A5 JP 2023546234 A JP2023546234 A JP 2023546234A JP 2023546234 A JP2023546234 A JP 2023546234A JP 2024505250 A5 JP2024505250 A5 JP 2024505250A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143025P | 2021-01-28 | 2021-01-28 | |
| US63/143,025 | 2021-01-28 | ||
| US202163183612P | 2021-05-03 | 2021-05-03 | |
| US63/183,612 | 2021-05-03 | ||
| US202163274893P | 2021-11-02 | 2021-11-02 | |
| US63/274,893 | 2021-11-02 | ||
| PCT/US2022/014156 WO2022165076A1 (en) | 2021-01-28 | 2022-01-27 | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505250A JP2024505250A (ja) | 2024-02-05 |
| JP2024505250A5 true JP2024505250A5 (cg-RX-API-DMAC10.html) | 2025-01-31 |
Family
ID=80447497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546234A Pending JP2024505250A (ja) | 2021-01-28 | 2022-01-27 | Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
Country Status (18)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| IL318410A (en) * | 2022-07-18 | 2025-03-01 | Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd | Polymorphic form of GLP-1R agonist, method of preparation thereof and use thereof |
| CN119923395A (zh) * | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| JP2025530809A (ja) * | 2022-09-06 | 2025-09-17 | 徳睿智薬（蘇州）新薬研発有限公司 | Ｇｌｐ－１ｒアゴニスト化合物の結晶多形物及びその製造方法と使用 |
| CN116102543B (zh) * | 2022-10-21 | 2025-07-22 | 江南大学 | 一种glp-1r激动剂、合成方法及其用途 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| EP4638455A1 (en) * | 2022-12-22 | 2025-10-29 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN120693333A (zh) * | 2023-01-19 | 2025-09-23 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的制造方法与中间体及其用途 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025128561A1 (en) | 2023-12-11 | 2025-06-19 | Carmot Therapeutics, Inc. | Crystalline forms of a glp-1 receptor modulator |
| CN122374306A (zh) | 2023-12-11 | 2026-07-10 | 卡莫特医疗有限公司 | Glp-1受体调节剂的盐型 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2025259888A1 (en) | 2024-06-13 | 2025-12-18 | Carmot Therapeutics Inc. | Method of treating diabetes using a glp-1 receptor agonist |
| WO2026047102A1 (en) | 2024-08-29 | 2026-03-05 | F. Hoffmann-La Roche Ag | Process for the preparation of pyrimidine derivatives |
| WO2026162461A1 (en) | 2025-01-29 | 2026-08-06 | F. Hoffmann-La Roche Ag | A glp-1 receptor modulator for use in the treatment of metabolic diseases, including diabetes |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| EA202191432A1 (ru) * | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| ES3029360T3 (en) * | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) * | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023538408A (ja) * | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒ作動薬としての化合物 |
| JP2023538949A (ja) * | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP7812052B2 (ja) * | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
-
2022
- 2022-01-27 US US18/262,956 patent/US20240252492A1/en not_active Abandoned
- 2022-01-27 GE GEAP202616925A patent/GEAP202616925A/en unknown
- 2022-01-27 EP EP22704219.9A patent/EP4284795A1/en active Pending
- 2022-01-27 CA CA3209593A patent/CA3209593A1/en active Pending
- 2022-01-27 CN CN202610424176.2A patent/CN122344190A/zh active Pending
- 2022-01-27 BR BR112023015045A patent/BR112023015045A2/pt unknown
- 2022-01-27 WO PCT/US2022/014156 patent/WO2022165076A1/en not_active Ceased
- 2022-01-27 GE GEAP202316333A patent/GEP20267901B/en unknown
- 2022-01-27 US US17/586,751 patent/US20230089073A1/en not_active Abandoned
- 2022-01-27 KR KR1020237029178A patent/KR20230152011A/ko active Pending
- 2022-01-27 CR CR20230330A patent/CR20230330A/es unknown
- 2022-01-27 JP JP2023546234A patent/JP2024505250A/ja active Pending
- 2022-01-27 MX MX2023008854A patent/MX2023008854A/es unknown
- 2022-01-27 EP EP25162106.6A patent/EP4563199A3/en active Pending
- 2022-01-27 AU AU2022212019A patent/AU2022212019A1/en active Pending
- 2022-01-27 IL IL304521A patent/IL304521B1/en unknown
- 2022-01-27 PE PE2023002212A patent/PE20231814A1/es unknown
-
2023
- 2023-07-26 JO JOJO/P/2023/0167A patent/JOP20230167A1/ar unknown
- 2023-07-26 CL CL2023002204A patent/CL2023002204A1/es unknown
- 2023-07-27 EC ECSENADI202357029A patent/ECSP23057029A/es unknown
- 2023-08-24 CO CONC2023/0011071A patent/CO2023011071A2/es unknown
-
2024
- 2024-04-11 US US18/632,736 patent/US20250092025A1/en not_active Abandoned
- 2024-08-08 CL CL2024002388A patent/CL2024002388A1/es unknown
-
2025
- 2025-01-14 US US19/020,628 patent/US12459929B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520648A5 (cg-RX-API-DMAC10.html) | ||
| JP2024517847A5 (cg-RX-API-DMAC10.html) | ||
| JP2016512536A5 (cg-RX-API-DMAC10.html) | ||
| JP2016512535A5 (cg-RX-API-DMAC10.html) | ||
| JP2016512534A5 (cg-RX-API-DMAC10.html) | ||
| CA2932010C (en) | Urea derivative or pharmacologically acceptable salt thereof | |
| DE60205564T2 (de) | N-Adamantylalkyl Benzamide Derivativen als p2x7-rezeptor antagonisten | |
| FI84479C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 2-amino-5-hydroxi-4- -metylpyrimidinderivat. | |
| JP2012503664A5 (cg-RX-API-DMAC10.html) | ||
| US5877199A (en) | Heterocyclic compounds, their preparation and their therapeutic use | |
| AU593278B2 (en) | Pharmaceutically active 2-thiomethyl-substituted-1,4- dihydropyridines | |
| SK280882B6 (sk) | Cyklické močoviny, ich analógy a farmaceutické prípravky na ich báze | |
| JP2024516291A5 (cg-RX-API-DMAC10.html) | ||
| JP2008503585A (ja) | カンナビノイドレセプターリガンド | |
| KR19990082330A (ko) | 신규 화합물 및 이의 의약 용도 | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JPH0285277A (ja) | １―インドリルアルキル―４―（置換ピリジニル）ピペラジン | |
| CA2195845A1 (en) | 1,2-substituted imidazolyl compounds for the treatment of inflammation | |
| TW200800182A (en) | Nitrogen-containing heterocyclic derivatives substituted by ring-type groups | |
| AU733604B2 (en) | 4-tetrahydropyridylpyrimidine derivative | |
| CZ20022352A3 (cs) | 4-pyridinyl-N-acyl-L-fenylalaniny | |
| JP2025032196A5 (cg-RX-API-DMAC10.html) | ||
| JPH02204479A (ja) | １，３，４，５―テトラヒドロベンズ［ｃ，ｄ］インドール | |
| JP2005511656A (ja) | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 | |
| WO2010121382A1 (en) | Process for making indole cyclopropyl amide derivatives |